Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- MHLW Approves Additional Indications for 8 Products Including AZ’s Symbicort
August 15, 2012
- Neo-Morgan Laboratory Developing a Variety of Organisms Using “Disparity Mutagenesis Technology”
August 14, 2012
- Drug Marketing Authorization Holders Submitted 36,641 Adverse Event Reports in FY2011: MHLW
August 14, 2012
- MHLW to Include Generic Drug Share Targets in Next 5-Year Medical Spending Optimization Plans in Response to Requests by Insurers
August 10, 2012
- MHLW Requires Revision of Package Inserts for 8 APIs including Oxaliplatin
August 9, 2012
- JPMA Calls for Maintenance and Expansion of R&D Tax Credit System at DPJ Hearings
August 9, 2012
- MHLW Study Group Takes Pass on Setting Up Relief System for Victims of Anticancer Drug Damage, Calling for Further Consideration by Government
August 8, 2012
- MOF Wants Generic Drug Share to Reach European, US Levels: Budget Examiner Shinkawa
August 8, 2012
- Talks between Health Minister, Plaintiff/Lawyer Groups Break Down on 3rd-Party Organization
August 7, 2012
- PAFSC’s First Committee Recommends Orphan Drug Designation for LAL Deficiency Treatment
August 7, 2012
- PAFSC’s First Committee Recommends Approval for Takeda’s Lotriga
August 7, 2012
- Health Minister Komiyama Continues Requesting IPV Price Cut
August 6, 2012
- DTP-IPV to Be Introduced in November; MHLW Anticipates Supply of 1.47 Million Doses by End of FY2012
August 6, 2012
- Ratio of Generics Rises 0.3 Points to 23.8%: Survey
August 3, 2012
- PMDA Determines Role of Science Board to Enhance Review System
August 2, 2012
- Council Generally Approves Revised Basic Policy for 2nd Med. Expenditure Optimization Plan; Regional Targets for Use of Generics to Be Included
August 2, 2012
- MHLW Investigative Commission Compiles Report to Improve Distribution of Novel Influenza Vaccines
August 1, 2012
- Council Approves Economic Revitalization Strategy with Priority on 3 Sectors Including Life Science
August 1, 2012
- MHLW to Issue Development Requests for 8 Drugs/Indications Determined to Have Unmet Medical Needs by Council on Unapproved Drugs
August 1, 2012
- MHLW Withdraws Development Request for Decitabine in Response to Approval for New Drug with Same Indication
August 1, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…